Research Activity – Page 7

Pfizer’s Embattled Obesity Program Loses Another GLP-1 Drug Due to Data and Competition Issues

1 month ago talkbio0Tagged Agonist, Clinical Trials, competition, Danuglipron, Drug Development, Glucagon-Like Peptide 1, Injury of liver, lotiglipron, Obesity, PF-06954522, Pfizer

Pfizer; obesity; GLP-1 agonist; clinical trial; liver injury; danuglipron; lotiglipron; PF-06954522; obesity drug development; competition

Scientists Protest FDA’s Rejection of Replimune’s Tumor Destroying Therapy

1 month ago talkbio0Tagged Clinical Trials, Drug Approval, Heterogeneity, IGYNTE, melanoma, Oncolytic Immunotherapy, Rejection, Replimune, RETINITIS PIGMENTOSA 1, scientist protest, United States Food and Drug Administration

Replimune; RP1; FDA rejection; oncolytic immunotherapy; melanoma; clinical trial; IGYNTE study; scientist protest; drug approval; patient heterogeneity

Praxis Seizure Drug Vormatrigine Shows Strong Efficacy in Phase 2 Trial

1 month ago talkbio0Tagged Clinical Research, Epilepsy, focal onset seizures, Praxis Precision Medicines, Radiant heater, Seizures, Sodium Channel Blockers, vormatrigine

Praxis Precision Medicines; vormatrigine; epilepsy; seizures; RADIANT study; focal onset seizures; Phase 2 trial; sodium channel blocker

Praxis touts ‘best-in-disease’ epilepsy data, but shares dip

1 month ago talkbio0Tagged anti-seizure medication, Clinical Research, Clinical Trials, Epilepsy, focal onset seizures, Market, Praxis Precision Medicines, Radiant heater, Seizures, vormatrigine

Praxis Precision Medicines; epilepsy; vormatrigine; RADIANT study; focal onset seizures; Phase 2 trial; seizure reduction; clinical trial; anti-seizure medication; stock market

Spine BioPharma’s Phase 3 Back Pain Drug Fails to Meet Primary Endpoint, Attributes Miss to High Sham Response

1 month ago talkbio0Tagged Chronic low back pain, Clinical Trials, Intervertebral Disc Degeneration, primary endpoint, Response process, salicylhydroxamic acid, SB-01, Spine BioPharma

Spine BioPharma; Phase 3 trial; chronic low back pain; degenerative disc disease; SB-01; primary endpoint; sham response; clinical trial results

Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications

1 month ago talkbio0Tagged China, Clinical Trials, Dosage Forms, Ecosystem, global drug development, Industry, innovation, Legal patent, US-China competition

China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition

Viridian Licenses Promising Eye Disease Candidates to Kissei for Japanese Market

1 month ago talkbio0Tagged Antibodies, Biopharma, Clinical Trials, Dosage Forms, Japan, Kissei, Partnership, Thyroid associated opthalmopathies, Veligrotug, Viridian, VRDN-003

Viridian Therapeutics; Kissei Pharmaceutical; veligrotug; VRDN-003; thyroid eye disease; Japan partnership; anti-IGF-1R antibodies; clinical trials; biopharma deal

Clinical Roundup: Cardiff, VYNE and NewAmsterdam Report Key Trial Results in Multiple Disease Areas

1 month ago talkbio0Tagged Alzheimer 's disease, BROADWAY trial, Cardiff Oncology, Clinical Trials, Metastasis from malignant neoplasm of colon and/or rectum, Neoplasms, NewAmsterdam Pharma, onvansertib, Statistical Significance, Vyne

Cardiff Oncology; VYNE; NewAmsterdam Pharma; clinical trial updates; onvansertib; metastatic colorectal cancer; Alzheimer’s disease; BROADWAY trial; oncology; statistically significant results